Stockscreener 앱 받기
5.73
0.35%
0.02
시장 영업 전:
5.70
-0.03
-0.52%
Nuvation Bio Inc 주식(NUVB)의 최신 뉴스
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug - Stocktwits
September 2026's High Insider Ownership Growth Leaders - simplywall.st
What Nuvation Bio (NUVB)'s Updated Cancer Drug Label Means For Shareholders - simplywall.st
Nuvation Bio Inc. (NUVB): Investor Outlook With A 115.82% Potential Upside - DirectorsTalk Interviews
Nuvation Bio stock gains on FDA label update for IBTROZI By Investing.com - Investing.com Australia
Why Is Nuvation Bio Stock Gaining Thursday? - Benzinga
Nuvation Bio stock gains on FDA label update for IBTROZI - Investing.com
Nuvation Bio Inc. (NUVB) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore
Nuvation Bio stock rises on Ibtrozi label update (NUVB:NYSE) - Seeking Alpha
Nuvation Bio Inc. (NYSE:NUVB) Wins FDA OK To Add ~50-Month DOR To IBTROZI Label - TradingView
A cancer drug showed responses lasting nearly four years. FDA approved Nuvation Bio's label update. - Stock Titan
Nuvation Bio (NUVB) Reports Consistent IBTROZI Results Across ROS1 Positive NSCLC Subgroups - simplywall.st
Nuvation Bio (NUVB) Reports IBTROZI Efficacy Across ROS1 Lung Cancer Subgroups - finance.yahoo.com
Citizens maintains Nuvation Bio stock rating on competitive edge - Investing.com
Nuvation Bio presents subgroup analyses for lung cancer drug By Investing.com - Investing.com South Africa
J.P. Morgan Maintains Nuvation Bio(NUVB.US) With Buy Rating - Moomoo
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer - Investing News Network
Nuvation Bio presents subgroup analyses for lung cancer drug - Investing.com
Nuvation Bio Inc. (NYSE:NUVB) Reports Consistent IBTROZI Efficacy Across ROS1+ NSCLC Subgroups - TradingView
Nearly 9 in 10 patients responded to a lung cancer drug after chemotherapy. - Stock Titan
Nuvation Bio (NUVB) Stock Looks Stretched Despite Its 354% Three Year Run - webull.com
NUVB: IBTROZI dominates ROS1 with best-in-class efficacy, while safusidenib advances across glioma subtypes - TradingView
Nuvation Bio at 12th Annual Cantor Fitzgerald Global Healthcare Conference: pipeline gains - Investing.com
NUVB: IBTROZI’s superior efficacy and safety drive rapid market share gains, with a strong pipeline advancing - TradingView
Nuvation Bio at citigroup biopharma summit: growth rests on three pillars - Investing.com Canada
NUVB: IBTROZI and safusidenib drive growth with best-in-class efficacy and expanding global opportunities - TradingView
NUVB: IBTROZI and safusidenib drive strong growth, with major clinical and commercial milestones ahead - TradingView
Nuvation Bio (NUVB) Slips to $6.52 as Traders Weigh Support and Resistance LevelsDefined Outcome ETF - careplusvn.com
Jim Cramer sends strong 5-word message on surging biotech stock - Yahoo Finance
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is... - Benzinga
Cramer's lightning round: Nuvation Bio 'is a pure spec' - CNBC
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect? - Yahoo Finance
Nuvation Bio to Participate in Upcoming Investor Conferences - Investing News Network
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why - Yahoo Finance
Nuvation: Why I'm Downgrading To Hold Despite Progress On NSCLC And Glioma Fronts (NUVB) - Seeking Alpha
NUVB|Nuvation Bio Inc|Price:7.100|Chg%:+0.340 - TradingKey
Nuvation Bio | 4: Statement of changes in beneficial ownership of securities-Officer Hattersley Gary - Moomoo
Nuvation Bio (NUVB) CSO sells 100K shares at $7.09 - Stock Titan
Nuvation Bio stock rises after Cantor starts at Overweight - Investing.com
Why is Nuvation Bio stock rallying today? By Investing.com - Investing.com Canada
Nuvation Bio rises as Cantor initiates at overweight - Seeking Alpha
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating - Investing.com
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating By Investing.com - Investing.com India
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma - Investing News Network
JPMorgan sees 100% upside in overlooked cancer drug stock - thestreet.com
FDA grants Nuvation fast-track status for safusidenib in IDH1-mutant glioma - AllSci
Nuvation Bio receives FDA fast track status for brain cancer drug - Investing.com South Africa
Market Sentiment Around Loss-Making Nuvation Bio Inc. (NYSE:NUVB) - Moomoo
One NYSEListed Biotechnology Stock at Resistance Level – NUVB - kalkine.ca
Nuvation (NUVB) Results Breakdown: EPS Comes in Above Forecast for the Current Session; Share Response - Vinanet
Nuvation Bio Inc (NUVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
This cancer drug stock could double as its treatment hits the market, JPMorgan says - CNBC
Nuvation wins new Overweight at J.P. Morgan (NUVB:NYSE) - Seeking Alpha
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know - Yahoo Finance
JPMorgan Initiates Nuvation Bio at Overweight With $13 Price Target - marketscreener.com
1.11%
1.87%
자본화:
|
볼륨(24시간):